Processos Inflamatórios Crônicos do Complexo AréoloPapilar: Fisiopatologia e Princípios Terapéuticos

1. Aloysio D, Altieri P, Bottiglioni F: Dieci anni

di esperienza clinica sulla terapia sostitutiva

con estrogeni coniugati equini nella postmenopausa. Bol Università degli Studi di

Bologna, 1989.

2. Brincat M, Versi E, Moniz CF,etal: Collagen

changes in post menopausal women receiving

diferent regimens of strogen therapy. Obstet

Gynecol, 7:840-845, 1987.

3. Sarrel P: Genital blood flow and ovarian

secretion. Clinical Practice in Sexuality, Special

issue: 14-15, 1990.

4. Lindsay R, Hart DM, Clark DN: The minimum

effective dose o estrogen for prevention of

postmenopausal bone loss. Obstet Gynecol,

63:759, 1984.

5. Lobo RA: Cardiovascular implication or

estrogenreplacementtherapy. Obstet Gynecol

75: 185-255, 1990.

6. Gambrell RDK (Jr): Estrogen replacement

therapy. 2ª Ed. EMIS Dallas, 1990.

7. Henderson BE, Paganini-Hell A, Ross RK:

Estrogen replacement therapy and protectionfrom acute myocardial infarction. A J Obstet

Gynecol, 159:312-317, 1988.

8. Filella MC: Aspectos clinicos en la

menopausia. In Palacios S (E): Climaterio Y

Menopausia, Mirpal, Madrid, 1992, pp:64-68.

9. Thomas TM, Plymat KR, Blannin J, Meade

TW: Prevalence of urinary incontinence,. Br

Med J, 281:1243-1245, 1980.

10. Stein JH: Alteraciones de los lipídeos Y de

las lipoproteínas. Medicina Interna - Tomo II -

2ª ed. Salvat, 1987, pp:2117-2134.

11. Kannel W, Hjorthand MC, McNamara Pm,

Gordon T: Menopause and risk of

cardiovascular disease: The Framingham

Study. Ann Intern Med, 85:447-452, 1976.

12. Steinleitner A, Stanczik FZ,, Levin JHetal:

Decrease in vitro of production of 6-ketoprostaglandin F1-alfa by uterine arterie from

postmenopausal women. Am J Obstet

Gynecol,161:1677-1981, 1989.

13. Sarrel PM: Ovarian hormones and the

circulation. Maturitas, 590:287-298, 1990.

14. Lewis AF: Fracture of neck of the femur:

Changing incidence. Br Med J, 283:1217-

1220, 1981.

15. Gil - Antuñano SP, Ceño CM:

Epidemiologia, clínica, diangóstico Yscreening

de la osteoporoses postmeopausica. In:

Palacios S(Ed) Climaterio y Menopausia,

Mirpal, Madrid, ,1992. pp:129-136.

16. Selby PL, Francis RM: Endocrinology and

osteoporosis. J. Endocrinol, 117:1-3, 1988.

17. Berrino F, Crosignani P, Gatta G, Macaluso

M, Pisani P, Viganò C. Incidenza dei tumori ecause di morte in Lombardia, March 1986.

18. Bonadonna G. Neoplasie della mamella.

In: Manuale di Oncologia Medica. Bonadonna

G and Robustelli G. (Eds.) Masson Italia, 3a

Ed, chapter 30, pp: 419-446, 1987.

19. Costa A, Love R. R. The Madison Meetings.

Breastcancer prevention with Tamoxifen.Eur.

J. Cancer 26:657-659, 1990.

20. Cuzick J, Wang DY, Bulbook RD. The

prevention of breast cancer. Lancet 1:83-86,

1986.

21. Fentiman I. S. The endocrine prevention

of breast cancer. Br. J. Cancer 60: 12-14,

1989.

22. Fischer B, Constantino J, Redmond C

Poisson R, Bowman D, Couture J et al. A

randomized clinical trial evaluating Tamoxifen

in the treatmentof patients with node-negative

breast cancer who have oestrogen-receptorpositive tumours. New England J. Med, 320

(8): 479-484, 1989.

23. Love R. R. Prospects for antioestrogen

chemoprevention of breast cancer. J. N. C. I,

82 (1): 18-21, 1990.

24. Miller A. B, Bulbrook R. D. UICС

multidisciplçinary project on breast cancer:

The epideiology and prevention of breast

cancer. Int. J. Cancer 37:173-177, 1986.

25. Powles TJ, Hardy JR, Ashley SE,

Farrington GM, Cosgrove D, Davey J B et al.

A pilot trial to evaluate the acute toxicity and

feasibility ofTamoxifen for prevention of breast

cancer. Br J. Cancer 60:126-131, 1989.

26. Vorherr H. Breast Cancer. Epidemiology,

Endocrinology, Biochemestry and Pathobiology, Urban - Scharzenberg. (Eds). Baltimore, USA 1990.

27. Pike MC, Ross RK, Lobo RA et al. LHRY

agonists and the prevention of breast and

ovarian cancer. Br J. Cancer, 60:1:142, 1989.